ProCE Banner Activity

HPTN 084 Update: Long-Acting Injectable CAB vs Daily Oral TDF/FTC for HIV PrEP in Cisgender Women

Slideset Download
Conference Coverage
An additional 1 year of unblinded follow-up of the HPTN 084 study continues to support superiority of long-acting injectable CAB vs daily oral TDF/FTC in reducing incident HIV infection among cisgender women at high risk.

Released: August 03, 2022

Expiration: August 02, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare


IAS 2021

ProCE Banner